Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86519 trials found · Page 75 of 4326
-
Donated cord blood cells engineered to fight tough cancers
Disease control Recruiting nowTo find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancer
Disease control OngoingThe purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
New bladder cancer treatment could outperform standard therapy
Disease control OngoingThe purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetreli…
Phase: PHASE3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 20, 2026 16:17 UTC
-
Scientists launch first human trial of 'Living Drug' for deadly brain tumors
Disease control Recruiting nowThe goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Personalized cell shot tested in battle against deadly brain cancer
Disease control OngoingThe purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
Phase: PHASE2 • Sponsor: Imvax • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Teen assault prevention program shows promise in new study
Prevention CompletedSexual violence (SV) perpetrated by dating partners and male acquaintances is common among adolescent girls in high school. Girls and young women who experience SV are likely to encounter negative mental and physical health consequences as well as lowered academic performance. Wh…
Phase: NA • Sponsor: University of Windsor • Aim: Prevention
Last updated Apr 25, 2026 18:46 UTC
-
New combo treatment could save stroke patients even hours after attack
Disease control CompletedTo assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
New pill challenges standard chemo for common blood cancer
Disease control OngoingResearchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
New approach aims to tame inflammation before Life-Saving transplant
Disease control Recruiting nowThe researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The res…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Decade-Long watch: tracking boys after experimental gene therapy for devastating muscle disease
Disease control TerminatedThe purpose of this study is to understand the safety and effects of an experimental gene therapy called fordadistrogene movaparvovec. We are seeking participants from previous Pfizer interventional studies. We will follow participants' experience in this study for 10 years after…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 09, 2026 19:34 UTC
-
Gene-Edited immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
Phase: PHASE1, PHASE2 • Sponsor: CRISPR Therapeutics AG • Aim: Disease control
Last updated Apr 25, 2026 18:42 UTC
-
Twice-Yearly shot aims to prevent heart attacks in High-Risk patients
Prevention OngoingCKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at high cardiovascular (CV) risk without a prior major …
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Prevention
Last updated Apr 24, 2026 16:20 UTC
-
New hope for kids battling tough leukemia
Disease control Recruiting nowThe objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who showed newly emerging or persistent MRD after a first stem cell transplantation, received stem cell tr…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Apr 17, 2026 16:12 UTC
-
New Triple-Threat attack on tough pancreatic cancers
Disease control Recruiting nowThis phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery (borderline resectable) or that has spread to nearby tissue …
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 13, 2026 20:20 UTC
-
Engineered immune cells target HPV cancers in new trial
Disease control Recruiting nowThis is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditio…
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Transplant showdown: can donor cells beat back returning blood cancer?
Disease control TerminatedAllogeneic stem cell (allo SCT) transplantation for multiple myeloma is a potential curative treatment, but is associated with morbidity and treatment related mortality. Approved drug combinations or another autologous stem cell transplantation (auto-SCT) can be used for relapsed…
Phase: PHASE3 • Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
New pill challenges standard shot in advanced breast cancer fight
Disease control OngoingA study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New Two-Pronged attack tested for tough blood cancers
Disease control OngoingThis research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lis…
Phase: PHASE2 • Sponsor: Patrick C. Johnson, MD • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Scientists weaponize immune cells to attack Virus-Linked cancer
Disease control CompletedEpstein-Barr virus (EBV) infections is known to be a high-risk factor to induce cervical cancers. To date, EBV-related nasopharyngeal carcinoma (NPC) is still a major concern in east Asia, especially in China. Concurrent therapies for NPC have limited response rate and high chanc…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Apr 13, 2026 20:16 UTC
-
Donor immune cells target deadly brain tumors in new cancer trial
Disease control Recruiting nowThis phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV melanoma that has spread to the brain (metastatic to t…
Phase: PHASE1, PHASE2 • Sponsor: Kari Kendra • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC